|Bid||65.00 x 100|
|Ask||71.38 x 100|
|Day's range||69.22 - 72.89|
|52-week range||60.08 - 107.44|
|Beta (3Y monthly)||0.47|
|PE ratio (TTM)||34.08|
|Earnings date||31 Oct. 2018 - 5 Nov. 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||104.24|
NEW YORK, Sept. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
After receiving two buyout offers this summer, the company forged its own path forward -- one that stuffs the balance sheet with around $590 million.
On a per-share basis, the Beijing-based company said it had profit of 83 cents. Earnings, adjusted for non-recurring costs, were $1.17 per share. The biopharmaceutical company posted revenue of $120.4 ...
Ping An Insurance (Group) Co., China’s largest insurer by market value, is considering a rival offer for plasma treatment provider China Biologic Products Holdings Inc., people familiar with the matter said. An arm of Ping An is in talks with other investors about a potential joint bid for Beijing-based China Biologic, according to the people, who asked not to be identified because the information is private. Any offer would be higher than the $110-per-share proposal from Chinese buyout firm Citic Capital, which valued U.S.-listed China Biologic at about $3.6 billion, the people said.
Stocks slid lower Monday as global markets remained rattled by the U.S.-China trade standoff. China stocks were highly active, however, led by JD.com.
Assessing China Biologic Products Holdings Inc’s (NASDAQ:CBPO) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple senseRead More...
On a per-share basis, the Beijing-based company said it had net income of 92 cents. Earnings, adjusted for non-recurring costs, came to $1.21 per share. The biopharmaceutical company posted revenue of ...